title: Future of personalized medicine in oncology: a systems biology approach.
abstract: The development of cost-effective technologies able to comprehensively assess DNA, RNA, protein, and metabolites in patient tumors has fueled efforts to tailor medical care. Indeed validated molecular tests assessing tumor tissue or patient germline DNA already drive therapeutic decision making. However, many theoretical and regulatory challenges must still be overcome before fully realizing the promise of personalized molecular medicine. The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient outcomes. Systems biology integrates engineering, physics, and mathematical approaches with biologic and medical insights in an iterative process to visualize the interconnected events within a cell that determine how inputs from the environment and the network rewiring that occurs due to the genomic aberrations acquired by patient tumors determines cellular behavior and patient outcomes. A cross-disciplinary systems biology effort will be necessary to convert the information contained in multidimensional data sets into useful biomarkers that can classify patient tumors by prognosis and response to therapeutic modalities and to identify the drivers of tumor behavior that are optimal targets for therapy. An understanding of the effects of targeted therapeutics on signaling networks and homeostatic regulatory loops will be necessary to prevent inadvertent effects as well as to develop rational combinatorial therapies. Systems biology approaches identifying molecular drivers and biomarkers will lead to the implementation of smaller, shorter, cheaper, and individualized clinical trials that will increase the success rate and hasten the implementation of effective therapies into the clinical armamentarium.
authors.affiliation: Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, USA. agonzalez@mdanderson.org
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Gonzalez-Angulo
authors.forename: Bryan T J
authors.initials: BT
authors.lastname: Hennessy
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D014408:Biomarkers, Tumor / Q000235:genetics; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D005260:Female; D005544:Forecasting; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics; D057285:Precision Medicine / Q000379:methods / Q000639:trends*; D011379:Prognosis; D040901:Proteomics; D049490:Systems Biology / Q000379:methods / Q000639:trends*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
references.citation: Int J Cancer. 1995 Aug 22;64(4):280-5
references.pmid: 7657393
references.citation: Cell. 2003 Nov 26;115(5):523-35
references.pmid: 14651845
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1130-6
references.pmid: 19124802
references.citation: Nat Genet. 2007 Jan;39(1):75-9
references.pmid: 17143282
references.citation: Cancer Cell. 2007 Oct;12(4):395-402
references.pmid: 17936563
references.citation: Cancer Res. 2009 Jan 1;69(1):143-50
references.pmid: 19117997
references.citation: Nat Genet. 2005 Jan;37(1):48-55
references.pmid: 15608639
references.citation: Nat Med. 2004 Nov;10(11):1251-6
references.pmid: 15502842
references.citation: Cell Cycle. 2009 Jun 15;8(12):1872-6
references.pmid: 19440052
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Cancer Cell. 2006 Dec;10(6):529-41
references.pmid: 17157792
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2079-85
references.pmid: 19671763
references.citation: N Engl J Med. 2009 Feb 19;360(8):790-800
references.pmid: 19228622
references.citation: Clin Cancer Res. 1998 Dec;4(12):2925-9
references.pmid: 9865902
references.citation: Expert Rev Mol Diagn. 2009 Oct;9(7):651-7
references.pmid: 19817550
references.citation: Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15
references.pmid: 15239896
references.citation: Adv Biochem Eng Biotechnol. 2002;77:57-74
references.pmid: 12227737
references.citation: Genes Chromosomes Cancer. 2006 Nov;45(11):1033-40
references.pmid: 16897746
references.citation: Nature. 2006 Jan 19;439(7074):353-7
references.pmid: 16273092
references.citation: J Clin Oncol. 2005 Mar 20;23(9):2020-7
references.pmid: 15774793
references.citation: J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
references.pmid: 2041050
references.citation: Clin Cancer Res. 2007 May 15;13(10):2890-6
references.pmid: 17504988
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: Ann N Y Acad Sci. 2008 Sep;1138:136-45
references.pmid: 18837894
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Nucleic Acids Res. 2008 Nov;36(20):6535-47
references.pmid: 18927117
references.citation: Proteomics. 2003 Nov;3(11):2085-90
references.pmid: 14595806
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61
references.pmid: 12461184
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34
references.pmid: 14623978
references.citation: Nat Methods. 2007 Oct;4(10):855-60
references.pmid: 17767164
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):417-9
references.pmid: 19147744
references.citation: APMIS. 2008 Jul-Aug;116(7-8):629-37
references.pmid: 18834407
references.citation: Cancer Res. 2008 Aug 1;68(15):6084-91
references.pmid: 18676830
references.citation: Nat Genet. 2007 Mar;39(3):347-51
references.pmid: 17293865
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9
references.pmid: 16172393
references.citation: Oncogene. 2007 Oct 25;26(49):6997-7005
references.pmid: 17486065
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9
references.pmid: 18852474
references.citation: Nat Med. 2008 Dec;14(12):1351-6
references.pmid: 19029981
references.citation: Cancer Res. 2006 Feb 1;66(3):1500-8
references.pmid: 16452206
references.citation: Cancer Res. 2009 May 15;69(10):4116-24
references.pmid: 19435916
references.citation: Proteomics. 2003 Nov;3(11):2142-6
references.pmid: 14595813
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1169-77
references.pmid: 15718313
references.citation: Lab Invest. 2004 Feb;84(2):235-44
references.pmid: 14767488